- Home
- MIRM vs FAF Comparison
MIRM vs FAF Comparison
Compare MIRM & FAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIRM | FAF |
|---|---|---|
| Founded | 2018 | 1889 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.8B |
| IPO Year | 2019 | 2009 |
Fundamental Metrics
Financial Performance| Metric | MIRM | FAF |
|---|---|---|
| Price | $99.83 | $72.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $119.85 | $82.50 |
| AVG Volume (30 Days) | ★ 700.1K | 698.2K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.09% |
| EPS Growth | 74.59 | ★ 376.19 |
| EPS | N/A | ★ 3.33 |
| Revenue | $19,138,000.00 | ★ $7,452,200,000.00 |
| Revenue This Year | $26.22 | $7.85 |
| Revenue Next Year | $22.04 | $5.57 |
| P/E Ratio | ★ N/A | $21.98 |
| Revenue Growth | N/A | ★ 21.61 |
| 52 Week Low | $63.23 | $56.20 |
| 52 Week High | $130.00 | $79.87 |
Technical Indicators
Market Signals| Indicator | MIRM | FAF |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 49.71 |
| Support Level | $88.08 | $64.75 |
| Resistance Level | $107.51 | $79.87 |
| Average True Range (ATR) | 4.27 | 1.61 |
| MACD | -0.39 | -0.43 |
| Stochastic Oscillator | 44.10 | 22.76 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About FAF First American Corporation (New)
First American Financial Corp is engaged in the business of providing title insurance, settlement services, and other financial services and risk solutions. The group's reportable segments are: Title insurance and services, Home warranty, and Corporate. Maximum revenue is generated from the Title insurance and services segment, which provides title insurance, closing, escrow, and related services domestically and internationally in connection with residential and commercial real estate transactions. This segment also provides solutions to mitigate risk and facilitate real estate transactions, along with offering banking, trust, warehouse lending, mortgage subservicing and wealth management services. The majority of the group's revenue is generated from escrow fees and insurance premiums.